When patients suffer from acute respiratory distress syndrome (ARDS), every decision counts. A recent analysis suggests that using hyper-oncotic albumin, a type of protein solution, may reduce mortality compared to traditional crystalloid fluids. In the studies reviewed, 33.2% of patients receiving albumin died, compared to 44.9% of those receiving crystalloid solutions. This is significant because it highlights a potential way to improve survival rates in critically ill patients. However, the results varied between different types of studies. While non-randomized studies showed a strong benefit from hyper-oncotic albumin, randomized controlled trials did not find the same advantage. Additionally, patients receiving albumin experienced better oxygenation, especially in the first two days of treatment. Despite these promising findings, the analysis emphasizes the urgent need for larger, high-quality studies to confirm the benefits of hyper-oncotic albumin and clarify its role in treating ARDS. For patients and families facing this serious condition, these insights could lead to better treatment options in the future.
Hyper-oncotic Albumin Reduces Mortality in ARDS Compared to CrystalloidCould hyper-oncotic albumin save lives in patients with severe lung issues?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider hyper-oncotic albumin for ARDS as it may reduce mortality compared to crystalloids.
A systematic review and meta-analysis evaluated the impact of albumin administration on mortality in adult patients with acute respiratory distress syndrome (ARDS), comparing it to crystalloid solutions. The analysis included five studies: three randomized controlled trials (RCTs) and two non-randomized studies (NRSs). The primary endpoint was 28-day mortality, with secondary outcomes including oxygenation changes and lengths of ICU and hospital stay. Overall, mortality was lower in the albumin group (33.2%, 97/292) compared to the crystalloid group (44.9%, 133/296), with an odds ratio (OR) of 0.61 (95% CI 0.43-0.85, p=0.004). While RCTs (n=204) showed no mortality benefit (OR=0.83, p=0.54), NRSs (n=384) demonstrated reduced mortality with albumin (OR=0.52, p=0.002). Specifically, hyper-oncotic albumin was associated with lower mortality in NRSs (OR=0.40, p=0.02) but not in RCTs (OR=0.74, p=0.57). Iso-oncotic albumin showed no mortality benefit (OR=0.88, p=0.72). Significant improvements in oxygenation were noted on the first (p=0.05) and second days (p<0.0001) post-administration. The trial sequential analysis highlighted the need for more high-quality RCTs to confirm these findings and clarify the clinical role of hyper-oncotic albumin in ARDS management.
What this means for you:
Hyper-oncotic albumin may lower mortality in ARDS patients compared to standard fluids. More on Acute Respiratory Distress Syndrome
Prediction models show moderate discrimination for ARDS occurrence and mortality in sepsis patients
Machine Learning Models Show Mixed Results for Predicting Sepsis Lung Injury
This systematic review and meta-analysis evaluated prediction models for ARDS occurrence and short-term mortality in patients with sepsis-as…
New analysis shows that while machine learning can predict lung injury in sepsis patients, these models do not consistently outperform stand…
Metabolomics profiles show elevated phenylalanine and lactate alongside depleted sphingosine 1-phosphate and citrulline in ARDS patients
Metabolomics profiles reveal metabolic signatures in patients with acute respiratory distress syndrome
This systematic review and meta-analysis examines metabolomics profiles in patients with acute respiratory distress syndrome compared to tho…
A new analysis shows specific chemical changes in the blood of patients with acute respiratory distress syndrome compared to those without t…
Evidence-based review of transducer selection for lung ultrasound in dogs and cats with pulmonary pathology
Choosing the right ultrasound probe can improve lung diagnoses for dogs and cats
This evidence-based review examines transducer selection for lung ultrasound in dogs and cats with pulmonary pathology.
Veterinary lung ultrasound accuracy depends on probe choice. This review highlights how transducer selection affects diagnosis in emergency …
Lung Ultrasound Shows Good Diagnostic Accuracy for ARDS in Meta-Analysis of 5888 Patients
Lung ultrasound shows high accuracy for detecting severe breathing trouble in ICU patients
This systematic review and meta-analysis of 5888 patients found that lung ultrasound (LUS) has good diagnostic accuracy for acute respirator…
A large review of 5,888 patients found lung ultrasound is a highly accurate, safe way to check for severe lung injury without using radiatio…
View Original Abstract ↓
BACKGROUND: To evaluate the association between albumin administration as volume replacement and mortality in adult ARDS patients, we performed this meta-analysis and trial sequential analysis (TSA).
METHODS: We searched databases including PubMed, Science Direct, Scopus, Web of Science databases and Cochrane Central Register of Controlled Trials up to 12 December 2024. We screened trials that included adult ARDS patients and compared albumin with crystalloid. The 28-day mortality served as the primary endpoint, while the oxygenation change, the length of ICU stay and the length of hospital stay were designated as secondary outcomes. To clarify the differing concentrations of albumin, we formed two distinct subgroups: the hyper-oncotic albumin subgroup (≥20%) and the iso-oncotic albumin subgroup (4%∼5%). Statistical synthesis was performed with Cochrane Review Manager 5.4.1, employing random-effects models. To mitigate random errors, TSA was implemented with α = 0.05 and β = 0.20 parameters.
RESULTS: The analysis incorporated 5 publications: 3 randomized controlled trials (RCTs) and 2 non-randomized studies (NRSs). Overall mortality was lower in the albumin group (33.2%, 97/292) than in the crystalloid group (44.9%, 133/296) (OR = 0.61, 95%CI 0.43-0.85, = 0.004). RCTs ( = 204) showed no benefit (OR = 0.83, = 0.54), but NRSs ( = 384) demonstrated reduced mortality (OR = 0.52, = 0.002). Hyper-oncotic albumin was associated with lower mortality in NRSs (OR = 0.40, = 0.02) but not in RCTs (OR = 0.74, = 0.57). Iso-oncotic albumin showed no benefit (OR = 0.88, = 0.72). Regarding the impact of albumin on oxygenation, significant improvements in oxygenation were observed only on the first ( = 0.05) and second days ( < 0.0001). The TSA indicated a continued need for high-quality RCTs.
CONCLUSIONS: Our analysis suggests that hyper-oncotic albumin may reduce mortality and improve early oxygenation in ARDS patients compared to crystalloids. Larger RCTs are urgently needed to validate these findings and define their potential role in clinical management.
Real-world meta-analysis supports pembrolizumab for advanced NSCLC with high PD-L1
Real-world data confirms pembrolizumab offers long-term survival for advanced lung cancer patients
Related in Pulmonology & Critical Care
FDA Approves Provocholine (methacholine chloride) for Bronchial Airway Hyperreactivity Diagnosis
FDA approves new test to help diagnose asthma in certain patients
The FDA approved Provocholine (methacholine chloride) for diagnosing bronchial airway hyperreactivity in adults and children aged 5 years an…
The FDA approved Provocholine, a drug used in a breathing test to diagnose airway hyperreactivity in people aged 5 and older who may have as…
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Lower PEEP may increase ventilator-free days in ventilated patients without ARDS
Lower breathing pressure settings showed modest benefits for some critically ill patients without lung injury
This Bayesian re-analysis of an RCT in 980 invasively ventilated critically ill patients without ARDS found that lower PEEP (0-5 cm H2O) com…
A re-analysis of data found that using the lowest safe breathing pressure might help some patients breathe easier. However, the overall bene…
Machine learning models show moderate accuracy predicting neoadjuvant immunotherapy response in NSCLC
Machine learning models predict how well lung cancer patients respond to immunotherapy
This systematic review and meta-analysis of 44 models found that machine learning predicts neoadjuvant immunotherapy response in resectable …
A new analysis of 44 models shows computer programs can guess which lung cancer patients will benefit from immunotherapy, though the study h…
From Other Specialties
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.